Figure 1 (Oxaliplatin Premier 01)
Oxaliplatin Injection, Solution, Concentrate
Product Images NDC 0955-1733
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 0955-1733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Winthrop U.s, A Business Of Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Oxaliplatin Premier 02)
This text appears to be a report or analysis of DFS (disease-free survival) probability in patients. It includes a graph showing the probability of DFS over time, with hazard ratio and logrank test results. The table below the graph shows the number of events and patients at risk in different arms. There are also percentages and numbers indicating how many patients experienced an event in each arm.*
Figure 2 (Oxaliplatin Premier 03)
This appears to be a graph or chart displaying the probability of DFS (Disease-Free Survival) over a period of time (measured in months). The graph also displays the hazard ratio and a Logrank Test probability. Two treatment arms are compared, FOLFOX4 and LV5FU2, both for the DUKES C cancer stage. The probability of DFS ranges from 0 to 0.9 with decreasing probability as time passes. The specific units of measurement and the exact nature of the study are not available.*
Figure 3 (Oxaliplatin Premier 04)
The text describes a graph showing the median survival rate of patients taking ELOXATIN and 5-FUILV over a period of 24 months. The percentage of patients who survived is shown on the vertical axis, while the months are shown on the horizontal axis. The graph compares this treatment to another one called irinotecan plus 5-FUILV. The log rank test shows that Eloxatin plus 5-FUILV is superior to irinotecan plus 5-FUILV.*
Figure 4 (Oxaliplatin Premier 05)
This description is for OXALIplatin injection with a dosage of 50 mg/10 mL that should be administered through intravenous infusion. The medication is a cytotoxic agent, and it is not recommended to be mixed or added to any solution that contains sodium chloride/chloride. Use of OXALIplatin should be based on the full prescribing information. The document also contains phone numbers and addresses for the manufacturer.*
Principal Display Panel (10 mL Vial Carton)
This is a description of a medication with the name Oxaliplatin injection. The warning of the medication indicates that it is a cytotoxic agent, and the instructions recommend not adding or mixing it with sodium chloride or chloride-containing substances. The medication is an intravenous infusion. The package size is 100 mg/ 20 ml and 5 mg/ml, and the manufacturer is PremierPro RX.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
